Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triumeq in HIV-1-infected children < 12 years
NCT03760458Phase 2
Key facts
- Status
- Completed
- Start
- Sep 2020
- Primary completion
- Dec 2021
- Countries
- 4
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
- Drugs
- abacavir
- Conditions
- human immunodeficiency virus type 1 infection (HIV-1)
01
Overview
Phase 2, open-label trial of abacavir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by National Institute of Allergy and Infectious Diseases. Started Sep 2020; status: completed.
02
Design
- Study design
- Non-randomizedOpen-label
03
Registry description
The purpose of this study was to examine the pharmacokinetics, safety, and tolerability of abacavir/dolutegravir/lamivudine dispersible and immediate release tablets in children living with HIV less than 12 years of age.
Beyond the preview
Go deeper on NCT03760458.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03760458.